WO2023027170A1 - タンパク質の翻訳制御システム - Google Patents
タンパク質の翻訳制御システム Download PDFInfo
- Publication number
- WO2023027170A1 WO2023027170A1 PCT/JP2022/032192 JP2022032192W WO2023027170A1 WO 2023027170 A1 WO2023027170 A1 WO 2023027170A1 JP 2022032192 W JP2022032192 W JP 2022032192W WO 2023027170 A1 WO2023027170 A1 WO 2023027170A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mrna
- protein
- binding
- translation
- target
- Prior art date
Links
- 230000014616 translation Effects 0.000 title claims abstract description 138
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 17
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 252
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 167
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 164
- 210000004027 cell Anatomy 0.000 claims abstract description 163
- 230000027455 binding Effects 0.000 claims abstract description 141
- 238000013519 translation Methods 0.000 claims abstract description 119
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 73
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 73
- 102000044126 RNA-Binding Proteins Human genes 0.000 claims abstract description 67
- 101710159080 Aconitate hydratase A Proteins 0.000 claims abstract description 59
- 101710159078 Aconitate hydratase B Proteins 0.000 claims abstract description 59
- 101710105008 RNA-binding protein Proteins 0.000 claims abstract description 59
- 230000017730 intein-mediated protein splicing Effects 0.000 claims abstract description 52
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 52
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 48
- 108020004414 DNA Proteins 0.000 claims abstract description 35
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims description 34
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 32
- 230000004913 activation Effects 0.000 claims description 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 239000012190 activator Substances 0.000 claims description 12
- 238000003776 cleavage reaction Methods 0.000 claims description 8
- AOKQNZVJJXPUQA-KQYNXXCUSA-N N(7)-methylguanosine 5'-phosphate Chemical group C1=2N=C(N)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@H](COP(O)([O-])=O)[C@@H](O)[C@H]1O AOKQNZVJJXPUQA-KQYNXXCUSA-N 0.000 claims description 6
- 230000033228 biological regulation Effects 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 78
- 101800001133 Viral protein genome-linked Proteins 0.000 description 21
- 125000003729 nucleotide group Chemical group 0.000 description 18
- 108020003589 5' Untranslated Regions Proteins 0.000 description 17
- 125000003275 alpha amino acid group Chemical group 0.000 description 17
- 239000002773 nucleotide Substances 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 16
- 239000012634 fragment Substances 0.000 description 15
- 230000006870 function Effects 0.000 description 14
- 230000004048 modification Effects 0.000 description 14
- 238000012986 modification Methods 0.000 description 14
- 108020005345 3' Untranslated Regions Proteins 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 125000005647 linker group Chemical group 0.000 description 11
- 210000000130 stem cell Anatomy 0.000 description 10
- 239000003550 marker Substances 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 8
- 108091081024 Start codon Proteins 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 108700026244 Open Reading Frames Proteins 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 241000700605 Viruses Species 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000008707 rearrangement Effects 0.000 description 6
- 125000006850 spacer group Chemical group 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 108010013829 alpha subunit DNA polymerase III Proteins 0.000 description 5
- 210000004900 c-terminal fragment Anatomy 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 230000014621 translational initiation Effects 0.000 description 5
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 4
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 4
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000004020 luminiscence type Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 210000004898 n-terminal fragment Anatomy 0.000 description 4
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 210000001082 somatic cell Anatomy 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 229930024421 Adenine Natural products 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 description 3
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 108010079855 Peptide Aptamers Proteins 0.000 description 3
- 102100025460 Protein lin-28 homolog A Human genes 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 229960000643 adenine Drugs 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 2
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 101001082110 Acanthamoeba polyphaga mimivirus Eukaryotic translation initiation factor 4E homolog Proteins 0.000 description 2
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 2
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 101001082109 Danio rerio Eukaryotic translation initiation factor 4E-1B Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000714201 Feline calicivirus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 2
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- 241000369696 Vesivirus Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000005937 allylation reaction Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 210000004507 artificial chromosome Anatomy 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 210000000688 human artificial chromosome Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 108700043045 nanoluc Proteins 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 230000000754 repressing effect Effects 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- 229940045145 uridine Drugs 0.000 description 2
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- ZLOIGESWDJYCTF-UHFFFAOYSA-N 4-Thiouridine Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- ZLOIGESWDJYCTF-XVFCMESISA-N 4-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-XVFCMESISA-N 0.000 description 1
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical group BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
- 241000180579 Arca Species 0.000 description 1
- 241000710073 Bean yellow mosaic virus Species 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 241000506337 Canine vesivirus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000003718 Dual-Luciferase Reporter Assay System Methods 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000369733 Lagovirus Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241001205255 Lupinus mosaic virus Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 241000424623 Nostoc punctiforme Species 0.000 description 1
- 102000000470 PDZ domains Human genes 0.000 description 1
- 108050008994 PDZ domains Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000205663 Papaya leaf distortion mosaic virus Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 241000710078 Potyvirus Species 0.000 description 1
- 229930185560 Pseudouridine Natural products 0.000 description 1
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 230000026279 RNA modification Effects 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 241000714203 Rabbit hemorrhagic disease virus Species 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 102000000395 SH3 domains Human genes 0.000 description 1
- 108050008861 SH3 domains Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 244000090125 Solidago odora Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- FHHZHGZBHYYWTG-INFSMZHSSA-N [(2r,3s,4r,5r)-5-(2-amino-7-methyl-6-oxo-3h-purin-9-ium-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl [[[(2r,3s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] phosphate Chemical compound N1C(N)=NC(=O)C2=C1[N+]([C@H]1[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=C(C(N=C(N)N4)=O)N=C3)O)O1)O)=CN2C FHHZHGZBHYYWTG-INFSMZHSSA-N 0.000 description 1
- 210000001943 adrenal medulla Anatomy 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 229940059260 amidate Drugs 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- -1 antibodies Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 210000000254 ciliated cell Anatomy 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000000555 contractile cell Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000005258 dental pulp stem cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000006200 ethylation reaction Methods 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000001813 extracellular matrix secreting cell Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003682 fluorination reaction Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 108700021021 mRNA Vaccine Proteins 0.000 description 1
- 229940126582 mRNA vaccine Drugs 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000006198 methoxylation reaction Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 230000001718 repressive effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 102200137695 rs1553850185 Human genes 0.000 description 1
- 102220004985 rs387906536 Human genes 0.000 description 1
- 102220105119 rs879254074 Human genes 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 210000001988 somatic stem cell Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000001086 yeast two-hybrid system Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
Definitions
- the present invention relates to a cell-selective protein translation control system using intracellular molecules as indicators and a translation control method used therein.
- mRNA medicines including mRNA vaccines.
- DNA the genetic material in the nucleus of the cell, is transcribed to produce mRNA, which is translated in the cytoplasm to produce proteins.
- mRNA drugs can express proteins that are useful for vaccines and disease treatment without the intervention of DNA in the nucleus by administering artificially synthesized mRNA from the outside.
- mRNA medicine is a new drug discovery modality that is attracting worldwide attention.
- mRNA drugs can respond to the expression of all proteins, including secretory proteins and intracellular signaling molecules. It has many advantages, such as the ability to express proteins and, in principle, to be applicable to all cells, including non-dividing cells.
- the present inventors have developed and reported an artificial translation control factor that has both protein translation activation and translation repression (see, for example, Non-Patent Document 1).
- This artificial translational regulator comprises a translational activator, a Cap-mimicking domain, and an RNA-binding protein.
- the artificial translational regulatory factor strongly binds to an mRNA comprising a Cap structure, a predetermined binding motif specifically recognized by the RNA-binding protein of the artificial translational regulatory factor, and a nucleic acid sequence encoding a desired protein. can bind and repress translation.
- the present inventors have constructed a system that introduces a fragment of a translation control factor into cells and reconstitutes a full-length translation control factor in response to any target molecule in the cell, such as a target protein. bottom.
- a target molecule such as a target protein.
- the present invention includes the following. [1] the following (a), (b) and (c): (a) mRNA expressing a first fusion protein containing a first target-binding molecule that specifically recognizes the first site of the target molecule, an N-terminal domain of a caged intein, and an N-terminal domain of a translation control factor , (b) expressing a second fusion protein comprising a second target-binding molecule that specifically recognizes the second site of the target molecule, the C-terminal domain of the caged intein, and the C-terminal domain of the translation control factor; mRNA, (c) a switch mRNA comprising one or more binding motifs that specifically recognize the translational control factor and a nucleic acid sequence encoding a target protein; or containing DNA encoding these,
- a protein translation control system wherein the translation control factor comprises an RNA-binding protein.
- the mRNA of (a) is a first mRNA containing a nucleic acid sequence encoding the first fusion protein
- the mRNA of (b) is a nucleic acid sequence encoding the second fusion protein.
- the system according to [1], wherein the second mRNA comprises [3]
- the mRNA of (a) and the mRNA of (b) are arranged in the 5' to 3' direction, a nucleic acid sequence encoding the second fusion protein, and a self-cleavage sequence encoding a self-cleavage peptide. and a nucleic acid sequence encoding said first fusion protein.
- the translation control factor comprises an RNA binding protein and a translation activation factor.
- the N-terminal domain of the translation control factor comprises the first part of the RNA-binding protein
- the C-terminal domain of the translation control factor comprises the second part of the RNA-binding protein
- the translation activation The system according to any one of [1] to [4], comprising a factor.
- the N-terminal domain of the caged intein is caged eNpu N-intein or a variant thereof
- the C-terminal domain of the caged intein is caged Npu C-intein or a variant thereof, [1]-[ 5], the system according to any one of the items.
- the switch mRNA is (A) an off-switch mRNA whose translation is repressed by the translation control factor, and/or (B) an on-switch mRNA whose translation is activated by the translation control factor and said off-switch mRNA comprises a Cap structure or a Cap analogue at the 5' end, one or more binding motifs that specifically recognize said RNA binding protein, and a nucleic acid sequence encoding a first protein of interest;
- the on-switch mRNA does not have a 7-methylguanosine 5'-phosphate structure and comprises one or more binding motifs that specifically recognize the RNA binding protein and a nucleic acid sequence encoding a second protein of interest.
- the binding motif for MS2CP is represented by the following formula (I): (In the formula, N 1 to N 15 each independently represent A, C, G or U; R represents G or A; Y represents U or C; N 1 and N 15 , N 2 and N 14 , N 3 and N 13 , N 4 and N 12 , N 5 and N 11 , N 6 and N 10 , and N 7 and N9 form a base pair or a wobble base pair, respectively.
- the off-switch mRNA contains two or more binding motifs that specifically recognize the MS2CP, and at least two of the two or more binding motifs are linked via an RNA scaffold structure, [8 ] or [9].
- a method for regulating protein translation comprising the step of introducing the system according to any one of [1] to [10] into a cell.
- a translation control factor can be reconstituted specifically for a cell type containing a desired target molecule.
- the translation control factor By allowing the translation control factor to act on the switch mRNA encoding the target protein, it becomes possible to suppress and/or activate the translation of the target protein.
- the translation control factor can be specifically reconstituted by any target molecule. Translational repression and/or translational activation can be achieved.
- FIG. 1 shows the state in which the first and second mRNAs are introduced into the cell and the first and second mRNAs are translated, and (B) shows the first fusion protein and the second fusion protein.
- C shows the rearranged full-length translational regulatory factor (left), the caged intein released by the action of the caged intein, the target-binding molecule, and the complex derived from the target protein. It is a conceptual diagram showing a body (right).
- FIG. 2 is a diagram schematically showing introduction of first, second, off-switch, and on-switch mRNAs into cells.
- FIG. 3 is a diagram schematically showing that the rearranged full-length translational control factor regulates both on-switch mRNA (lower left) and off-switch mRNA (lower right).
- Figure 4 (A) shows the plasmid DNA constructs designed in preliminary experiments with the Npu DnaE intein, (B) shows the N-terminus only, C-terminus only, and repressor at each split site.
- FIG. 10 is a graph showing results of translation repression by the constructed translation repression factor; FIG. FIG.
- 5(A) shows the plasmid DNA construct (left) encoding the first and second mRNAs according to Example 1 of the present invention, the DNA construct (upper right) encoding the off-switch mRNA, and the expression level of the target protein. It is a diagram showing a DNA construct encoding Nluc (middle right) and mRNA encoding the target protein eDHFR used as a control for the measurement, and (B) shows translation when each construct and mRNA were introduced into cells. It is a graph which shows a suppression result.
- FIG. 6A shows, in order from the top, the first mRNA according to Example 2 of the present invention, the second mRNA, the mRNA encoding the target protein eDHFR, the mRNA encoding EGFP as a negative control for the target protein, and Luc2 as the target protein.
- Fig. 2 shows the off-switch mRNA for Luc2, the on-switch mRNA for Luc2 as the target protein, and the Nluc-encoding mRNA used as a control for measuring the expression level of the target protein.
- FIG. 6B is a graph showing the results of translation suppression of off-switch mRNA when each mRNA was introduced into cells.
- FIG. 6C is a graph showing the results of translational activation of on-switch mRNA when each mRNA was introduced into cells.
- FIG. 7A shows, in order from the top, the first mRNA according to Example 3 of the present invention, the second mRNA, the mRNA encoding the target protein EGFP, the mRNA encoding eDHFR as a negative control for the target protein, and Luc2 as the target protein.
- Fig. 2 shows the off-switch mRNA for Luc2, the on-switch mRNA for Luc2 as the target protein, and the Nluc-encoding mRNA used as a control for measuring the expression level of the target protein.
- FIG. 7A shows, in order from the top, the first mRNA according to Example 3 of the present invention, the second mRNA, the mRNA encoding the target protein EGFP, the mRNA encoding eDHFR as a negative control for the target protein, and Luc2 as the target protein.
- FIG. 7B is a graph showing the results of translation suppression of off-switch mRNA when each mRNA was introduced into cells.
- FIG. 7C is a graph showing the results of translational activation of on-switch mRNA when each mRNA was introduced into cells.
- a system according to the present invention comprises: (a), (b) and (c) below: (a) mRNA expressing a first fusion protein containing a first target-binding molecule that specifically recognizes the first site of the target molecule, an N-terminal domain of a caged intein, and an N-terminal domain of a translation control factor , (b) expressing a second fusion protein comprising a second target-binding molecule that specifically recognizes the second site of the target molecule, the C-terminal domain of the caged intein, and the C-terminal domain of the translation control factor; mRNA, (c) a switch mRNA comprising one or more binding motifs that specifically recognize the translational control factor and a nucleic acid sequence encoding a target protein; or containing DNA encoding these, Said translation control element comprises an RNA binding protein.
- the system according to the present invention comprises a first target-binding molecule in which the mRNA of (a) specifically recognizes the first site of the target molecule and the N-terminal domain of the caged intein and the N-terminal domain of a translation control factor, wherein the mRNA of (b) specifically recognizes the second site of the target molecule
- a second mRNA comprising a nucleic acid sequence encoding a second fusion protein comprising a second target-binding molecule, the C-terminal domain of a caged intein, and the C-terminal domain of the translational control factor. That is, in the first embodiment, mRNA containing a nucleic acid sequence encoding a first fusion protein and mRNA containing a nucleic acid sequence encoding a second fusion protein are included as separate molecules.
- the protein translation control system and method according to the first embodiment will be described below.
- the method according to this embodiment includes the step of introducing the mRNAs of (a), (b) and (c) or DNAs encoding them into cells.
- This embodiment relates to a protein translation control system and method, and more particularly to a system and method for cell-selectively controlling the translation of a target protein using a target molecule as an index.
- Cell-selectively regulating the translation of a target protein using a target molecule as an indicator means that the translation of the target protein encoded by the switch mRNA of (c) can be controlled only in cells in which the target molecule is present. More specifically, translation of a protein of interest encoded by the switch mRNA in the presence of the reconstituted translational regulator relative to a control in the absence of the translational regulator or with the translational regulator split.
- a cell type that selectively induces translational control is also referred to as a target cell.
- other cell types are also collectively referred to as non-target cells.
- a translation control factor is generated based on the first fusion protein in which the mRNA of (a) is expressed and the second fusion protein in which the mRNA of (b) is expressed.
- the rearranged, rearranged translational control element enables control of the translation of the switch mRNA of (c).
- the target molecule refers to a molecule that exists in the target cell at the time of performing the method of the present invention, and in certain embodiments, it can refer to a molecule that exists in the cytoplasm or nucleus of the target cell. .
- the target molecule is not particularly limited as long as it has a first binding site and a second binding site that can be specifically recognized by other molecules. However, it is preferred that the first binding site and the second binding site on the target molecule are separate sites.
- Target molecules are also preferably non-toxic to cells. Specific examples of target molecules include proteins, peptides, non-peptide compounds, synthetic low-molecular-weight compounds, natural compounds, or fragments thereof.
- a target molecule can be appropriately selected according to the purpose of translational control.
- any molecule specific to the intracellular state to be detected can be a protein. or peptides.
- a low-molecular-weight compound that easily permeates the cell membrane can be selected.
- metabolites produced as a result of natural or artificial reactions in cells can also be target molecules, and in this case metabolites may be low-molecular-weight compounds and the like.
- a target molecule consisting of a protein or a fragment thereof is hereinafter also referred to as a target protein.
- a target protein is selected and determined for the purpose of selectively suppressing or activating the expression of a target protein in target cells, and based on the target protein, (a) and ( The mRNA of b) can be designed.
- the target protein it is preferable to select, for example, a protein that has a large difference in expression level or abundance between target cells and non-target cells.
- target molecules other than target proteins it is also preferable to select molecules that have a large difference in the amount present between target cells and non-target cells.
- target proteins include proteins that are endogenous to specific cells. Proteins that are endogenous to a particular cell include, but are not limited to, proteins that are expressed according to the differentiation stage of the cell and proteins that are expressed according to the disease state of the cell. By reconstituting translational control factors in response to the presence of these target proteins, translational control of target proteins encoded by switch mRNAs in cells at different stages of differentiation or in diseased cells characterized by each target protein is possible. It can be performed.
- Another example of a target protein is a protein produced due to a substance introduced exogenously into a cell.
- Proteins produced due to substances introduced from the outside include proteins that can be produced in the cells due to genes restored by genome editing, proteins that can be produced in the cells by mRNA vaccination or mRNA medicine. , proteins that can be produced in the cell by plasmid DNA, viral vectors, and the like, but are not limited to these.
- target molecules other than target proteins include molecules produced intracellularly in specific disease states and molecules artificially produced in cells, and the types thereof are not limited.
- cell is not particularly limited and may be any cell.
- a cell may be a single cell or a "cell population”, which is a collection of two or more cells. There is no theoretical upper limit to the number of "cell populations”, and they refer to populations composed of any number of cells.
- a "cell population” may be a cell population that may contain different types of cells, and may contain target cells and non-target cells.
- Cells may be cells collected from unicellular or multicellular organisms, or may be cells (including cell lines) that have been artificially manipulated. For example, yeast, insect cells, animal cells, etc. are used, and among them, animal cells are preferred.
- Animal cells include, for example, cells derived from mammals (eg, mice, rats, hamsters, guinea pigs, dogs, monkeys, orangutans, chimpanzees, humans, etc.).
- Cells derived from mammals include monkey COS-7 cells, monkey Vero cells, Chinese hamster ovary (CHO) cells, dhfr gene-deficient CHO cells, mouse L cells, mouse AtT-20 cells, mouse myeloma cells, and rats.
- Cell lines such as GH3 cells, human embryonic kidney-derived cells (e.g. HEK293 cells), human liver cancer-derived cells (e.g. HepG2), human FL cells, etc., and primary cells prepared from human and other mammalian tissues Cultured cells are used. Furthermore, zebrafish embryos, Xenopus laevis oocytes and the like can also be used.
- the cells may be (A) stem cells, (B) progenitor cells, (C) terminally differentiated somatic cells, or (D) other cells.
- stem cells include, but are not limited to, embryonic stem (ES) cells, embryonic stem (ntES) cells derived from cloned embryos obtained by nuclear transfer, spermatogonial stem cells ("GS cells”). , embryonic germ cells (“EG cells”), induced pluripotent stem (iPS) cells, and the like.
- Progenitor cells include, for example, tissue stem cells (somatic stem cells) such as neural stem cells, hematopoietic stem cells, mesenchymal stem cells, and dental pulp stem cells.
- Somatic cells include, for example, keratinizing epithelial cells (e.g., keratinizing epidermal cells), mucosal epithelial cells (e.g., tongue epithelial cells), exocrine gland epithelial cells (e.g., mammary gland cells), hormone secretion cells (e.g., adrenal medulla cells), cells for metabolism and storage (e.g., hepatocytes), luminal epithelial cells that make up the interface (e.g., type I alveolar cells), luminal epithelial cells of the inner chain duct ( vascular endothelial cells), ciliated cells with carrying capacity (e.g.
- airway epithelial cells extracellular matrix-secreting cells (e.g. fibroblasts), contractile cells (e.g. smooth muscle cells), blood and Immune system cells (e.g. T lymphocytes), sensory cells (e.g. rod cells), central and peripheral nervous system neurons and glial cells (e.g. astrocytes), pigment cells (e.g. retinal pigment epithelium) cells), and their progenitor cells (tissue progenitor cells).
- Other cells include, for example, cells that have undergone differentiation induction, including progenitor cells and somatic cells that have undergone differentiation induction from pluripotent stem cells.
- cells induced by so-called "direct reprogramming (also referred to as trans-differentiation)" in which somatic cells or progenitor cells are directly differentiated into desired cells without passing through an undifferentiated state, may be used.
- the first mRNA of (a) and the second mRNA of (b) are mRNAs that express the first and second fusion proteins, respectively.
- the first fusion protein contains the N-terminal domain of the translational regulator and the second fusion protein contains the C-terminal domain of the translational regulator. Then, when the target protein is present in the cell, it associates and reconstitutes the full-length translation control factor within the cell.
- FIG. 1(A) is a conceptual diagram showing a state in which the first and second mRNAs have been introduced into cells and the first and second mRNAs have been translated.
- FIG. 1(A) schematically represents the target protein (left), the first fusion protein (middle), and the second fusion protein (right).
- the first fusion protein is a substance produced by intracellular translation of the first mRNA. are combined in this order.
- the second fusion protein is a substance produced by intracellular translation of the second mRNA. linked in this order.
- FIG. 1(B) shows a state in which both the first fusion protein and the second fusion protein are bound to the target protein. This binds the N-terminal domain of the caged intein and the C-terminal domain of the caged intein. Then, by the action of the caged intein, the N-terminal domain and C-terminal domain of the translational regulatory factor bind to reconstitute the full-length translational regulatory factor.
- FIG. 1(C) shows the reconstructed full-length translational regulatory element (left), the caged intein released by the action of the caged intein, the target binding molecule, and the complex derived from the target protein (right).
- a translational regulator is generally an artificial translational regulator and includes at least an RNA binding protein. More specifically, the translation control factor used for translational repression comprises or consists of an RNA binding protein. Translational regulatory factors used for translational activation include RNA-binding proteins and translational activators. As used herein, the full-length translational control factor refers to a translational control factor after rearrangement of the N-terminal domain and the C-terminal domain, which has a translational control function on switch mRNA. and
- RNA-binding protein is a protein that specifically recognizes a specific RNA sequence and forms an RNA-protein complex.
- a specific RNA sequence that specifically recognizes and binds to such an RNA-binding protein is referred to herein as a "binding motif" or "protein-binding motif.” Any RNA-binding protein can be used in the present invention without any particular limitation as long as it can bind to the binding motif.
- the RNA-binding proteins include, for example, MS2CP, L7Ae, LIN28A, PP7CP, dCas13, variants thereof (for example, in the case of MS2CP, V29I variant, L77P variant, W82R variant, C101R variant, dlFG mutants, etc.), fragments thereof having RNA-binding ability, and the like. Activation and/or repression of translation of target proteins has already been demonstrated using MS2CP, L7Ae and LIN28A.
- the RNA binding protein is preferably MS2CP or a variant thereof.
- the RNA-binding protein is an amino acid sequence represented by any one of SEQ ID NOS: 5, 7 and 9 (nucleotide sequences encoding proteins consisting of each sequence are represented by SEQ ID NOS: 4, 6 and 8, respectively). ), one or several (for example, 2, 3, 4, 5) amino acids are deleted, substituted, inserted and/or 85% or more (e.g., 90%, 95%, 96%, 97%, 98%, 99% or more) of the added amino acid sequence or the amino acid sequence shown in any of SEQ ID NOS: 5, 7 and 9 A protein containing an amino acid sequence having the identity of .
- RNA-binding proteins include wild-type RNA-binding proteins, variants thereof, and fragments thereof.
- the translation activator is not particularly limited as long as it can recruit a translation initiation factor and activate translation.
- One aspect of the present invention includes a VPg (viral protein genome-linked) protein as a translation activator.
- VPg is used as an example of the translation activator.
- VPg should be read as another translation activator.
- the translation control system of the present invention is capable of activating or repressing protein translation with the above configuration.
- the VPg protein is not particularly limited as long as it has a protein translation activation function. and fragments thereof having a translation activation function.
- viruses belonging to the genus Vesivirus include feline calicivirus (NCBI Accession No: NP_783307.1), canine vesivirus (NCBI Accession No: NP_786908.1), porcine vesicle virus (NCBI Accession No: NP_786894.1), Viruses belonging to the Lagovirus genus include rabbit hemorrhagic disease virus VPg (NCBI Accession No: NP_740330.1), and viruses belonging to the Potyvirus genus include Lupinus mosaic virus, Bean yellow mosaic virus, and Papaya leaf distortion mosaic virus.
- the VPg protein has the amino acid sequence shown in SEQ ID NO: 3 (the nucleotide sequence encoding the protein consisting of this sequence is shown in SEQ ID NO: 2).
- VPg protein includes VPg protein, VPg protein variants and fragments thereof.
- the translational control factor that has both translational repression and translational activation functions may be a fusion protein containing an RNA-binding protein and a VPg protein.
- the translation control factor may be a protein-binding domain such as an SH3 domain, a PDZ domain, a GK domain, or a GB domain and a binding partner thereof fused to an RNA-binding protein and a VPg protein, respectively.
- the RNA-binding protein may exist on the N-terminal side and the VPg protein may exist on the C-terminal side, or the RNA-binding protein may exist on the C-terminal side and the VPg protein on the N-terminal side. and there may be a linker between them.
- the translation control factor having both translation repression and translation activation functions is a fusion protein between an RNA-binding protein and a VPg protein, which is the Caliciviral VPg- It may be a based Translational activator (CaVT).
- the translation control factor has the amino acid sequence shown in SEQ ID NO: 11 (the nucleotide sequence encoding the protein consisting of the sequence is shown in SEQ ID NO: 10), one or several in the amino acid sequence shown in SEQ ID NO: 11 (for example, 2, 3, 4, 5) amino acids are deleted, substituted, inserted and / or added, or the amino acid sequence shown in SEQ ID NO: 11 and 85% or more (e.g., 90%, 95 %, 96%, 97%, 98%, 99% or more) identity can be used.
- the translation control factor is divided into an N-terminal domain and a C-terminal domain.
- the location where the translation control factor is divided into the N-terminal domain and the C-terminal domain is not particularly limited as long as the following conditions are satisfied. That is, each domain before rearrangement does not have the action of translational repression or translation activation independently, the translational regulatory factor is rearranged by the caged intein, and the function of the translational regulatory factor is maintained after rearrangement. is.
- the translational control element is preferably split into N-terminal and C-terminal domains in the manner in which its essential component, the RNA-binding protein, is split.
- the three-dimensional structure of the RNA-binding protein is analyzed, it can be divided into an N-terminal domain and a C-terminal domain at a loop portion that does not constitute an ⁇ -helix or a ⁇ -sheet.
- the N-terminal domain of the translation control factor that has only a translation repressing function contains the N-terminal fragment of the RNA-binding protein
- the C-terminal domain contains the C-terminal fragment of the RNA-binding protein
- the N-terminal domain of the translational regulatory factor that has both translational repressive and translational-activating functions includes, in certain embodiments, an N-terminal fragment of an RNA-binding protein, and the C-terminal domain of the translational regulatory factor is an RNA-binding protein. Contains C-terminal fragment and translational activator.
- the N-terminal domain of the translational regulator comprises an N-terminal fragment of a translational activator and an RNA binding protein
- the C-terminal domain of the translational regulator comprises a C-terminal fragment of an RNA binding protein.
- the split point may be between the 45th tyrosine residue and the 46th cysteine residue, for example.
- the split point may be changed as long as it is within 5 amino acid residues from the split point to the N-terminal side or the C-terminal side, but in that case, it is preferable to select a site that does not constitute an ⁇ -helix or a ⁇ -sheet. . Appropriate division points can be confirmed by prior experiments and simulations by those skilled in the art.
- caged inteins are proteins that cause rearrangement only when there is an interaction through other domains. Defined as an intein with fused structures.
- a protein or peptide having a C-intein-like sequence can be used as a cage structure for N intein
- a protein or peptide having an N-intein-like sequence can be used as a cage structure for C intein.
- the other domains are the first and second target binding molecules.
- Any caged intein can be used.
- caged eNpu N-intein SEQ ID NO: 14
- the N-terminal domain of caged intein disclosed in Gramespacher J. A. et al., J. Am.
- the terminal domain caged Npu C-intein (SEQ ID NO: 15) can be used, but is not limited to these.
- Each sequence is shown in Table 1.
- the bold letters are the N intein-derived sequence (in SEQ ID NO: 14), the C intein-derived sequence (in SEQ ID NO: 15), the underlined portion is the linker sequence, and the boxed portion is the C intein-like sequence (in SEQ ID NO: 14). ), representing the N intein-like sequence (in SEQ ID NO: 15).
- the original N-intein-derived sequence is from the 1st residue to the 102nd residue.
- the 30-residue sequence from the 125th to the 154th residue and the 30-residue sequence from the 160th to the 189th residue are the same and are C-intein-like sequences.
- a sequence consisting of 22 residues from the 103rd residue to the 124th residue is a linker sequence of the N intein-derived sequence and the C intein-like sequence.
- a sequence consisting of five residues from the 155th to the 159th residue is a linker sequence between the C-intein-like sequences.
- the caged eNpu N-intein shown in SEQ ID NO: 14 is a sequence containing two repeats of a C-intein-like sequence, and the types of amino acids in the sequence with one repeat of the C-intein-like sequence, the sequence with three or more repeats, and the linker sequence. can also be used as well as caged eNpu N-inteins.
- the sequence consisting of 52 residues from the 1st residue to the 52nd residue is an N intein-like sequence, consisting of 22 residues from the 53rd residue to the 74th residue.
- the sequence is a linker sequence between the N-intein-like sequence and the C-intein-derived sequence, and the sequence consisting of 35 residues from the 75th to the 109th residue is the C-intein-derived sequence.
- a sequence in which the N-intein-like sequence in caged Npu C-intein has two or three or more repeats, and a sequence in which the type of amino acid in the linker sequence is changed can also be used in the same manner as in caged Npu C-intein.
- Mutants of caged eNpu N-intein and mutants of caged Npu C-intein can also be used as long as they do not impair the activity of the caged intein.
- mutants include mutants in which conservative substitutions are made to the amino acid sequences of SEQ ID NOS: 14 and 15, and one or several (e.g., 2, 3, 4, 5) amino acid sequences. ) amino acids are deleted, substituted, inserted and / or added, or amino acid sequences represented by SEQ ID NOS: 14 and 15 and 85% or more (e.g., 90%, 95%, 96%, 97%, 98%, 99% or greater) amino acid sequence identity.
- the first and second target-binding molecules are molecules that specifically recognize the first and second sites of the target molecule, particularly the target protein, respectively.
- the first and second target binding molecules can be selected or designed to match the target protein.
- the target-binding molecule may be any molecule that has the ability to bind to the target molecule, and when the target molecule is an antigen, antibodies, peptide aptamers, artificial peptides derived from fibronectin, DARPin, and the like can be mentioned. Even when the target molecule is a molecule other than protein, a molecule that specifically binds to the target molecule can be appropriately determined.
- low-molecular-weight compounds include target-binding molecules that utilize interactions such as rapamycin-mediated binding between FKBP (FK506-binding protein) and FRB (FKBP-rapamycin binding protein).
- the antibody used in the present invention is not particularly limited in origin, it is preferably mammalian in origin.
- Antibodies used in the present invention may be full-body antibodies, fragment antibodies (e.g., nanobody antibodies, Fab, F(ab') 2 , etc., or variants thereof (e.g., scFv, etc.).
- the term "antibody” is used to include these.
- the peptide aptamer used in the present invention may be a peptide in which amino acid residues or both terminal portions have been modified.
- Peptide aptamers can be selected using methods well known to those skilled in the art.For example, but not limited to, yeast two-hybrid method can be used.Other molecules are also known per se.
- the target-binding molecule may be an artificial molecule obtained by modifying a protein other than the antibody to have the same antigen-binding ability as the antibody. , anticalins, and the like.
- the first and second target-binding molecules are selected from the known target-binding molecules. can be selected.
- the first site and the second site are different parts, and the first site and the second site are proximal to each other as long as they do not inhibit the binding of the target binding molecule to each other.
- the interaction between the first site of the target protein and the first target-binding molecule and the interaction between the second site of the target protein and the second target-binding molecule cause rearrangement of the caged intein.
- the target binding molecule that specifically recognizes the target protein is unknown, or when only one target binding molecule is known, the target protein or its fragment is used as an antigen to immunize camelids such as alpaca. to generate antibodies and obtain the sequences of their antigen-recognition sites.
- target binding molecules such as two or more Nanobodies, that specifically recognize different sites of the target protein.
- a full-length translational control factor, the N-terminal domain of the translational control factor, the N-terminal domain of the caged intein, and the first target-binding molecule are selected or designed, the first fusion protein is designed, and the structure is determined.
- a second target binding molecule, the C-terminal domain of a caged intein, the C-terminal domain of a translational regulator can be selected or designed, and a second fusion protein can be designed and the structure determined.
- each domain may be directly linked or linked via a linker.
- the length of the linker is not particularly limited, it may be, for example, about 2 to 30 amino acids long, or about 2 to 15 amino acids long.
- the first mRNA comprises, in the 5′ to 3′ direction, [5′ UTR containing a Cap structure or Cap analog at the 5′ end], [an open reading frame containing a nucleic acid sequence encoding a first fusion protein ], [3′UTR containing PolyA] may be linked in this order.
- the 5'UTR of the first mRNA contains a Cap structure or Cap analog at the 5' end.
- the Cap structure may be a 7-methylguanosine 5' phosphate.
- the Cap analog is a modified structure recognized by eIF4E, which is a translation initiation factor similar to the Cap structure, and is manufactured by Ambion's Anti-Reverse Cap Analog (ARCA ), m7G(5')ppp(5')G RNA Cap Structure Analog from New England Biolabs, CleanCap from TriLink, and the like. Cap analogs may be other modified structures recognized by translation initiation factors.
- An arbitrary nucleic acid sequence of, for example, about 0 to 500 bases, preferably about 20 to 200 bases, may be contained on the 3' side of the Cap structure or Cap analog and on the 5' side of the initiation codon. These arbitrary nucleic acid sequences are preferably nucleic acid sequences that do not form secondary structures and do not specifically interact with the second mRNA. In addition, it is preferable that AUG, which serves as an initiation codon, does not exist within the 5'UTR.
- the open reading frame which is the coding region of the first mRNA, includes an initiation codon, a nucleic acid sequence encoding the first fusion protein, and a termination codon.
- the nucleic acid sequence encoding the first fusion protein comprises, from the 3' side of the initiation codon AUG to the 5' side of the stop codon, the nucleic acid sequence encoding the N-terminal domain of the translational control factor, the N-terminal domain of the caged intein. and a nucleic acid sequence encoding the first target binding molecule, in that order.
- the nucleic acid sequence encoding each domain can be determined from the structure of the previously designed first fusion protein.
- the 3'UTR of the first mRNA contains PolyA tail.
- a PolyA tail may be a sequence of about 50-250 adenine bases attached. However, it is not necessary that about 50 to 250 adenine bases are continuously linked, and other nucleobases may be included between the adenine bases as long as the stability of the mRNA can be maintained.
- the second mRNA comprises, in the 5′ to 3′ direction, [5′ UTR containing a Cap structure or Cap analog at the 5′ end], [an open reading frame containing a nucleic acid sequence encoding a second fusion protein ], [3′UTR containing PolyA] may be linked in this order. [5'UTR containing Cap structure or Cap analog at 5' end] and [3'UTR containing PolyA] may be the same as the first mRNA.
- the 5'UTR and 3'UTR nucleic acid base sequences and number of nucleic acid bases may be the same or different between the first mRNA and the second mRNA, but are preferably the same.
- the open reading frame which is the coding region of the second mRNA, includes an initiation codon, a nucleic acid sequence encoding the second fusion protein, and a termination codon.
- the nucleic acid sequence encoding the second fusion protein has a nucleic acid sequence encoding the second target binding molecule, the C-terminal domain of the caged intein, in the direction from 3' to the start codon AUG to 5' to the stop codon.
- the nucleic acid sequence encoding each domain can be determined from the structure of the previously designed second fusion protein.
- switch mRNA is an mRNA whose translation is controlled by a translational control factor.
- Switch mRNAs include on-switch mRNAs that are translationally activated by translational control factors and off-switch mRNAs that are translationally repressed. Both the on-switch mRNA and the off-switch mRNA contain one or more binding motifs that specifically recognize an RNA-binding protein that constitutes a translation control factor, and a nucleic acid sequence that encodes the target protein.
- a binding motif refers to a nucleic acid sequence that specifically recognizes a particular RNA-binding protein and forms an RNA-protein complex.
- the off-switch mRNA has a Cap structure or a Cap analogue at the 5' end, and comprises one or more binding motifs that specifically recognize an RNA-binding protein that constitutes a translational control factor, and a nucleic acid sequence that encodes the first target protein. including.
- the off-switch mRNA of the present invention typically has one or more binding motifs in the 5'UTR, and the binding motifs are stabilized by an RNA scaffold structure.
- the off-switch mRNA of the present invention preferably has binding motifs for two or more RNA-binding proteins, and at least two of the binding motifs are linked via an RNA scaffold structure.
- RNA scaffold structure means a structure that is linked to one or more binding motifs and thereby stabilizes the motifs. Structures having one or more stem regions due to base pairing are included. The base pairs of the stem region can be designed according to the desired stability (usually the number of base pairs forming the stem region is believed to improve stability).
- binding motifs When two or more binding motifs are linked, at least one of them should have a scaffold structure, but from the viewpoint of stability, it is preferable that all the binding motifs are linked. In addition, two or more motifs may be connected via other structures (eg, loop structures, etc.) without including a stem region or not including a stem region.
- stabilizing the binding motif means that compared to the case without a scaffold structure, fluctuations in the structure of RNA are reduced, and the probability that RNA has the potential secondary structure described below is increased. do.
- the binding motif for the RNA-binding protein contained in the off-switch mRNA of the present invention is not particularly limited as long as it binds to the protein. Binding of the RNA-binding protein to RNA via the binding motif suppresses translation of the target protein. Taking the case where the RNA-binding protein is MS2CP as an example, it can be designed appropriately by referring to known literature (eg Grahn E et al., RNA. 7(11):1616-1627 (2001)). can be done.
- At least one of the binding motifs has the following formula (I) (nucleotide sequence shown as SEQ ID NO: 1): (In the formula, N 1 to N 15 each independently represent A, C, G or U; R represents G or A; Y represents U or C; N 1 and N 15 , N 2 and N 14 , N 3 and N 13 , N 4 and N 12 , N 5 and N 11 , N 6 and N 10 , and N 7 and N9 form a base pair or a wobble base pair, respectively.
- formula (I) nucleotide sequence shown as SEQ ID NO: 1: (In the formula, N 1 to N 15 each independently represent A, C, G or U; R represents G or A; Y represents U or C; N 1 and N 15 , N 2 and N 14 , N 3 and N 13 , N 4 and N 12 , N 5 and N 11 , N 6 and N 10 , and N 7 and N9 form a base pair or a wobble base pair, respectively.
- N 1 is A
- N 2 is G or C (preferably G)
- N 3 is G
- N 4 is U
- N 5 is G
- N 6 is G
- N 7 is G
- N 8 is U
- N9 is C
- N10 is C
- N11 is C
- N12 is A
- N13 is U
- N14 is C or G (preferably C)
- N15 is U
- R is A
- Y is C A structure is mentioned.
- RNA having a potential secondary structure represented by n and m in formula (II) are each independently an integer of typically 1000 or less, preferably 100 or less (eg, 50, 20, 10, etc.).
- the potential secondary structure such as the structure represented by the above formula (I) or (II) is referred to as the "binding motif of the RNA-binding protein" (sometimes simply abbreviated as “binding motif”). and when the RNA-binding protein is MS2CP, it is also referred to as “MS2CP-binding motif”.
- Potential secondary structure refers to a secondary structure that stably exists under physiological conditions. & Kiryu, H. Parallel computation of genome-scale RNA secondary structure to detect structural constraints on human genome. BMC Bioinformatics 17, 203 (2016)).
- Xa and Xb when n and m are different integers, Xa and Xb have a bulge loop. Even when n and m are the same integer, Xa and Xb form The stem structure may have a bulge loop, but from the viewpoint of stability of the MS2CP-binding motif, a stem structure without a bulge loop is preferred.
- the off-switch of the present invention containing two MS2CP-binding motifs comprises a structure in which n and m are each independently 0 to 5 (e.g., 1) in formula (II) above, and Exemplary structures include structures in which n and m are 1 in formula (II) above, where Xa and Xb are C and G, respectively.
- n and m are each independently 5 to 10 (e.g., 7). 7, where Xa and Xb are ACGAGCG and CGCUCGU, respectively.
- RNA switch of the present invention contains two or more binding motifs
- at least two structures represented by structure (II) above may be linked via a multi-branched loop.
- the number of nucleotides in the hyperbranched loop is also not particularly limited, but is, for example, 4 to 10, or 5 to 9 (eg, 7).
- the multibranched loop may have another structure, for example, another multibranched loop (the multibranched loop may further have another structure such as a helix loop structure). For example, it may be linked to 0 to 10 (eg, 2 to 5) stem structures.
- an integrated structure composed of multiple secondary structures such as a structure having a plurality of structures represented by formula (II) and including a binding motif such as an MS2CP-binding motif, is referred to as an "RNA binding protein It is sometimes referred to as a "binding domain for” (sometimes simply abbreviated as “binding domain”).
- binding domains are typically formed from at least two types of structures selected from hairpin structures, helix structures, bulge loops, internal loops (inteRNAl-loops), multi-branched loops and pseudoknot structures. be done.
- binding motif L7Ae binding motif for example, known literature (e.g. Shi X et al., Nat Chem Biol. 12(3): 146-152 (2016)) can be appropriately designed in consideration of Specific examples include those having a structure represented by the following formula (III).
- the LIN28A binding motif can be appropriately designed in consideration of known literature (e.g., Kawasaki S et al., Nucleic Acids Res. 45(12): e117 (2017)). include those having a stem-loop structure containing the GGGAU sequence.
- it is also possible to control the degree of activation or repression of translation by appropriately designing the position, sequence, and structure of the binding motif in RNA, modification of nucleotide residues, and the like.
- N 1 to N 11 each independently represent A, C, G or U; N2 and N10 , and N3 and N9 form a base pair or a wobble base pair, respectively.
- the length of a binding motif can be any number of bases, and can generally be about 200 nucleotides or less, such as about 100 nucleotides or less, preferably about 50 nucleotides or less, more preferably about 40 nucleotides or less. Nucleotide or less.
- the length of the binding domain can also be any number of bases, and can typically be about 300 nucleotides or less, such as about 200 nucleotides or less, preferably about 150 nucleotides or less. If the total number of nucleotides is small, mass production is easier, and there is also a large cost advantage.
- the lower limit of the length of the binding motif and binding domain is not particularly limited as long as it contains the binding motif sequence (eg, the sequence represented by SEQ ID NO: 1). more than a nucleotide.
- the first target protein may be a protein that is the target of translational control, and the type of protein is not particularly limited.
- the protein of interest may be a nuclease and may be a Cas protein or variant thereof.
- the protein of interest may be anti-CRISPR, which inactivates Cas protein.
- the protein of interest may be a marker protein.
- a marker protein is a protein that is expressed from an mRNA switch, functions as a marker within a cell, and can identify the cell.
- a marker protein may be, by way of example, a protein that can be visualized and quantified, such as by fluorescence, luminescence, coloration, or by assisting fluorescence, luminescence or coloration.
- marker proteins include proteins that directly affect cell function. Examples include cell proliferation proteins, cell death proteins, cell signaling factors, drug resistance genes, transcription control factors, translation control factors, differentiation control factors, reprogramming inducers, RNA binding protein factors, chromatin control factors, and membrane proteins. but not limited to these.
- a cell proliferation protein functions as a marker by allowing only cells that express it to proliferate and identifying proliferated cells.
- a cell-killing protein kills the cell itself by inducing cell death of the cell in which it is expressed, and functions as a marker indicating whether the cell is alive or dead.
- a cell signaling factor is a marker that the cells in which it is expressed emits a specific biological signal, and the identification of this signal serves as a marker.
- Cell killing proteins are exemplified by, for example, Bax or Bim.
- the off-switch mRNA is preferably oriented from the 5' end to the 3' end [5'UTR with a Cap structure or Cap analog at the 5' end and containing a binding motif], [encoding the first protein of interest
- the open reading frame containing the nucleic acid sequence] and the [3'UTR containing PolyA] may be linked in this order.
- the Cap structure or Cap analog can be selected from the same options as for the first mRNA.
- the binding motif can be located anywhere on the 3' side of the Cap structure or Cap analog and upstream of the translation initiation codon (ie, 5'UTR). Since the translational activity of the on-switch of the present invention can be changed depending on the position of the binding motif within the 5'UTR, the position can be appropriately adjusted depending on the purpose.
- a spacer may optionally be included between the Cap structure or Cap analog and the binding motif, and/or between the binding motif and the initiation codon.
- the nucleic acid sequence of the spacer is not particularly limited as long as it does not form a secondary structure within the switch mRNA and does not interact with the first and second mRNAs.
- each spacer may be any number of bases, 0 to 800 bases, 0 to 700 bases, 0 to 600 bases, 0 to 500 bases, 0 to 450 bases, 0 to 400 bases, 0 to 350 bases, 0-300 bases, 0-250 bases, 0-200 bases, 0-150 bases, 0-100 bases, 0-50 bases, 0-40 bases, 0-30 bases, 0-20 bases or 0- 10 bases are exemplified.
- Base sequences such as restriction enzyme sites are also included in the base sequence of the spacer. Translational activity can be adjusted by adjusting the number of bases in the spacer.
- a specific example of the 5'UTR of the off-switch mRNA is the sequence shown in SEQ ID NO: 12 (AGGUCAGAUCCGCUAGCGGAUCCGGGAGCAGGUGAGGAUCACCCAUCUGCCACGAGCGAGGUGAGGAUCACCCAUCUCGCUCGUGUUCCCACCGGUCGCCCACC), but is not limited to a specific sequence.
- the 3'UTR containing PolyA of the off-switch mRNA can be designed in the same manner as the 3'UTRs of the first and second mRNAs.
- the off-switch mRNA functions to suppress the translation of the first target protein by specifically recognizing and binding its binding motif to the RNA-binding protein.
- the RNA-binding protein is MS2CP
- the higher the binding strength between MS2CP and the binding motif the lower the translational activity.
- translational activity is suppressed when a motif that binds to MS2CP is used in .
- MS2CP also has the function of suppressing translation by binding to the binding motif, and the translation level is mediated by the VPg protein.
- the off-switch of the present invention includes two or more binding motifs, and at least two of them are linked via a scaffold structure, the sequence of the binding motifs is changed, or the nucleotide residues are subjected to specific modifications. For this reason, it is thought that by increasing the binding ability to RNA-binding proteins to a certain level or higher, the protein's translation-suppressing action is induced without being limited to a specific structure.
- On-switch mRNA does not have a 7-methylguanosine 5'-phosphate structure at the 5' end, and encodes a binding motif that specifically recognizes an RNA-binding protein that constitutes a translational control factor, and a second target protein. and a nucleic acid sequence that
- the on-switch mRNA preferably has a modification at the 5' end that has only the former of the RNA degradation suppression effect and the translation activation effect that a normal Cap structure has. That is, any structure may be used as long as it is not recognized by eIF4E, which is a translation initiation factor. More specifically, it is preferable to have a structure that does not have a 7-methylguanosine 5'-phosphate structure at the 5' end. Modifications at the 5' end of on-switch mRNA include, for example, A-Cap (G(5')ppp(5')A).
- the on-switch mRNA typically has one or more binding motifs in the 5'UTR, and the binding motif is not particularly limited as long as it specifically recognizes and binds to the RNA-binding protein. Binding of the RNA-binding protein to RNA via the binding motif activates translation of the protein encoded by the RNA. Taking the case where the RNA-binding protein is MS2CP as an example, binding motifs include those having the structure represented by the above formula (II).
- the second target protein is a protein that activates the translation of the on-switch mRNA and increases the amount of translation.
- the second protein of interest can be selected from the same options as the substances exemplified as the first protein of interest.
- the first target protein and the second target protein can be appropriately selected according to the desired action.
- the first protein of interest and the second protein of interest are, for example, a combination of a protein having a positive activity and a protein having a negative activity with respect to the desired activity such as apoptosis activity and nuclease activity. can.
- Examples thereof include, but are not limited to, a combination of an apoptosis-inducing protein and an apoptosis-inhibiting protein, a combination of Cas protein and anti-CRISPR that inactivates Cas protein, and the like.
- the on-switch mRNA is preferably oriented from the 5' end to the 3' end [5'UTR without a 7-methylguanosine 5'-phosphate structure and containing a binding motif], [second protein of interest
- the open reading frame containing the nucleic acid sequence encoding] and [3'UTR containing PolyA] may be linked in this order.
- the 5'UTR of the on-switch mRNA should have a binding motif on the 3' side of the modified structure at the 5' end.
- the position of the binding motif in the 5'UTR and the sequence and number of spacers can be the same as those of the off-switch mRNA.
- a specific example of the 5'UTR of the on-switch mRNA is the sequence shown in SEQ ID NO: 13 (GGGCGAAUUAAGAGAGAAAAGAAGAGUACAUGAGGAUUACCCAUGUAAGAAGAAAUAUAAGACACCGGUCGCCACC), but is not limited to a specific sequence.
- the 3'UTR containing PolyA of the on-switch mRNA can be designed in the same manner as the 3'UTRs of the first and second mRNAs.
- Each of the first, second, and switch mRNAs described above may be modified at the sugar residue (ribose) of each nucleotide for the purpose of reducing cytotoxicity.
- Modified sites in the sugar residue include, for example, those in which the 2'-, 3'- and/or 4'-position hydroxy groups or hydrogen atoms of the sugar residue are replaced with other atoms.
- Types of modifications include, for example, fluorination, alkoxylation (e.g., methoxylation, ethoxylation), O-allylation, S-alkylation (e.g., S-methylation, S-ethylation), S-allylation. , amination (eg —NH 2 ).
- Such modification of sugar residues can be performed by a method known per se (for example, Sproat et al., (1991) Nucle. Acid. Res. 19, 733-738; Cotton et al., (1991) Nucl. Acid. Res. 19, 2629-2635; Hobbs et al., (1973) Biochemistry 12, 5138-5145).
- sugar residues of the first, second, and switch mRNAs can also be BNA: Bridged nucleic acid (LNA: Linked nucleic acid) that forms a crosslinked structure at the 2' and 4' positions. Modification of such sugar residues can also be performed by a method known per se (e.g., Tetrahedron Lett., 38, 8735-8738 (1997); Tetrahedron, 59, 5123-5128 (2003), Rahman S.M.A., Seki S., Obika S., Yoshikawa H., Miyashita K., Imanishi T., J. Am. Chem. Soc., 130, 4886-4896 (2008)).
- BNA Bridged nucleic acid
- the first, second, and switch mRNAs may have modified (eg, chemically substituted) nucleobases (eg, purines, pyrimidines).
- modified nucleobases eg, purines, pyrimidines
- modifications include, for example, pyrimidine modifications at position 5, purine modifications at positions 6 and/or 8, modifications with exocyclic amines, substitutions with 4-thiouridine, substitutions with 5-bromo or 5-iodo-uracil. mentioned.
- modified bases such as pseudouridine ( ⁇ ), N1-methylpseudouridine (N1m ⁇ ), and 5-methylcytidine (5mC) are included in place of normal uridine and cytidine. You can stay.
- the positions of the modified bases can be all or part of them independently, and when they are part, they can be random positions at any ratio.
- Phosphate groups (eg, terminal phosphate residues) contained in the first, second, and switch mRNAs of the present invention may be modified to enhance resistance to nucleases and hydrolysis, and the like.
- the P(O)O group serving as a phosphate group is P(O)S (thioate), P(S)S (dithioate), P(O)NR 2 (amidate), P(O)R, R( O) optionally substituted with OR', CO or CH2 (formacetal) or 3'-amine (-NH- CH2 - CH2- ), wherein each R or R' is independently H or substituted or unsubstituted alkyl (eg, methyl, ethyl)].
- the linking group is exemplified by -O-, -N- or -S-, and can be linked to adjacent nucleotides through these linking groups.
- the present inventors have confirmed that, depending on the type of RNA modification, there is a difference in the binding strength between the RNA-binding protein and the binding motif for the protein. Therefore, by appropriately changing the type of modification, it is also possible to adjust the binding strength between the RNA-binding protein and the binding motif for the protein. Specific modifications to the above nucleobases, sugar residues and phosphate residues are shown below, but are not limited to these.
- the first, second, and switch mRNAs can be synthesized by those skilled in the art by any method known in genetic engineering, once the molecular structures and nucleic acid sequences are determined according to the above. For example, it can be obtained as a synthetic mRNA molecule by an in vitro transcription method using a template DNA containing a promoter sequence as a template.
- FIG. 2 is a diagram schematically showing introduction of first, second, off-switch, and on-switch mRNAs into cells. Introduction of mRNA into cells can be performed in vitro or in vivo, and is not particularly limited.
- RNA molecules can be introduced directly into cells.
- Introduction of the first, second, and switch mRNAs into cells in vivo can use any method commonly used to introduce RNA into cells in vivo.
- Methods for directly introducing RNA molecules into cells include, for example, the lipofection method, the polymer method, the electroporation method, the calcium phosphate coprecipitation method, the DEAE dextran method, the microinjection method, and the gene gun method.
- RNA molecules can be introduced directly into cells.
- Introduction of the first, second, and switch mRNAs into cells in vivo can use any method commonly used to introduce RNA into cells in vivo.
- introduction methods such as intramuscular, subcutaneous, intravenous, and intra-articular injection.
- the advantage of introducing synthetic RNA molecules is that the introduced mRNA is degraded with a half-life of about several days, so there is no integration into the genome, and the cells after introduction can be easily used for medical applications. be done.
- the synthetic mRNA since the synthetic mRNA has a high transfection efficiency, it is possible to express a predetermined amount of the first and second fusion proteins in the cell, and to introduce the switch mRNA for expressing the target protein with high efficiency. It is advantageous in that it is possible to
- the first, second and switch mRNAs are preferably co-introduced into the cell. Since the activity ratio of the proteins expressed from the two or more co-introduced mRNAs becomes constant in the cell, the first fusion protein, the second fusion protein, and the switch mRNA can be introduced at a constant ratio. It's for.
- DNA constructs such as RNA expression vectors can also be used to introduce the first, second, and switch mRNAs into cells.
- expression vectors encoding the first, second, and switch mRNAs can be designed separately, and the two expression vectors can be directly introduced into cells by the same introduction method as described above.
- Expression vectors encoding the sequences of the first mRNA and the second mRNA can be well-known and commonly used in the art. For example, a virus vector, an artificial chromosome vector, a plasmid vector, an expression system using a transposon (sometimes called a transposon vector) and the like.
- viral vectors examples include retroviral vectors, lentiviral vectors, adenoviral vectors, adeno-associated viral vectors, Sendai viral vectors and the like.
- artificial chromosome vectors include human artificial chromosomes (HAC), yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC, PAC) and the like.
- a plasmid vector mammalian plasmids in general can be used, and for example, an episomal vector can be used.
- transposon vectors include expression vectors using piggyBac transposons. It is also possible to design DNA constructs that express two or more of the first mRNA, the second mRNA, the switch mRNA as separate mRNAs from a single RNA expression vector.
- the first mRNA and the second mRNA are transcribed from the expression vector and generated by being transcribed in the cell.
- the mRNA and switch mRNA can function like a directly introduced synthetic mRNA molecule to express the first fusion protein and the second fusion protein.
- the method of introducing the DNA construct into the cell is advantageous, for example, when integrating into the genome of the cell to prepare a cell stably expressing the first fusion protein, the second fusion protein and the switch mRNA, It is advantageous in selecting or discriminating those that have been pre-incorporated into pluripotent stem cells or transgenic animals and differentiated into specific cell types.
- the amount of the first, second, and switch mRNAs to be introduced into the cell varies depending on the type of target cell and the structure of the mRNA, and is not limited to a specific amount.
- the introduction amount that can achieve translational regulation of the desired protein of interest in target cells can be determined by preliminary experiments and the like.
- the first and second mRNAs introduced into the cell generate the first and second fusion proteins within the cell (Fig. 1 (A)).
- the first target-binding molecule and the second target-binding molecule specifically recognize and bind to the first site and second site of the target protein, respectively.
- a complex is formed in which the caged intein N-terminal domain of the first fusion protein and the caged intein C-terminal domain of the second fusion protein are bound (Fig. 1(B)).
- a complex consisting of the target protein, the first target-binding molecule, the second target-binding molecule, and the bound caged intein is released from the complex in FIG.
- the rearranged translational control factor acts on the switch mRNA to control translation.
- the first fusion protein expressed from the mRNA of and the second fusion protein exist in the cell as separate proteins without binding, that is, the translation control factor is not reconstituted.
- the first fusion protein and the second fusion protein are not reconstituted, they do not control the translation of the switch mRNA, and the expression of the target protein encoded by the switch mRNA is not controlled.
- the translational control method comprises the step of introducing into a cell at least four types of mRNA, a first mRNA, a second mRNA, an off-switch mRNA, and an on-switch mRNA (Fig. 2 ).
- a complex of the first and second fusion proteins expressing the first and second mRNAs is produced, and the translation control factor is reconstituted.
- the translational control factor specifically recognizes and binds to on-switch mRNA and off-switch mRNA by means of RNA-binding proteins. Then, translation of the target protein encoded by the on-switch mRNA can be activated, and translation of the target protein encoded by the off-switch mRNA can be suppressed.
- the protein translational control system according to the present invention can also be provided as a translational control kit containing the first mRNA, the second mRNA, the switch mRNA, or the DNAs encoding these.
- the translation control kit includes a medium suitable for culturing cells including target cells, and instructions for handling the first mRNA, the second mRNA, the switch mRNA, or the DNA encoding these.
- the instructions may include information such as experimental methods for determining the appropriate amount of mRNA to be introduced in a particular cell, and the appropriate amount to be introduced depending on the cell type.
- a kit comprising the protein translation control system according to this embodiment enables cell-selective protein translation control.
- the (a) mRNA and the (b) mRNA may be a single mRNA.
- This single mRNA may be such that one mRNA molecule is capable of expressing the first and second fusion proteins as separate and distinct molecules. More specifically, a single mRNA comprises, in 5' to 3' orientation, a nucleic acid sequence encoding said second fusion protein, a self-cleavage sequence encoding a self-cleavage peptide, and said first fusion. and a nucleic acid sequence that encodes the protein.
- the 5'UTR and 3'UTR can be designed in the same way as the first or second mRNA above. and the open reading frame is, in the 5′ to 3′ direction, a nucleic acid sequence encoding the second fusion protein, a self-cleavage sequence encoding the self-cleavage peptide, and a nucleic acid encoding the first fusion protein.
- Arrays can be designed to contain, in that order.
- the self-cleaving peptide may be a viral 2A peptide or a 2A-like peptide with similar functions. Examples include, but are not limited to, F2A, E2A, T2A, P2A, and the like. Modifications of sugar residues in the design of mRNA molecules may be modified as described in the first embodiment.
- the translation control method according to the second embodiment also includes the step of introducing a single mRNA expressing the first and second fusion proteins and the switch mRNA into a cell.
- the translation control system and method according to the second embodiment eliminates the need to separately prepare and introduce the first and second mRNAs, and the possibility that some cells express only either the first or second fusion protein. has the advantage of eliminating
- Template DNA was prepared by PCR using PrimeSTAR Max DNA Polymerase and purified with Monarch PCR & DNA Cleanup Kit (New England Biolabs). Using this template DNA as a template, transcription reaction was carried out at 37°C for about 6 hours using MEGAscript T7 Transcription Kit (Thermo Fisher Scientific). At this time, 6 mM ATP, CTP, GTP, N1-methylpseudoUTP and 4.8 mM CleanCap Reagnt AG (3'OMe) (TriLink) were used as NTP and Cap analog.
- RNACleanXP Natural Genetics
- Quick CIP New England Biolabs
- RNeasy Mini Kit Qiagen
- RNA concentration was measured with Nanodrop ONE.
- the size of the purified mRNA was confirmed using a Bioanalyzer and RNA 6000 Nano Kit (Agilent Technologies, Inc.). Template DNA names and sequence numbers are shown in Table 3 below.
- ⁇ Introduction of plasmid DNA into cells > 1 ⁇ 10 4 HeLa cells were seeded in each well of a 96-well transparent flat-bottomed white plastic plate and cultured in a CO 2 incubator at 37° C. for one day. After that, pDNA was transfected into cells in each well with 0.3 ⁇ l of TransIT-X2 (Takara Bio).
- ⁇ Introduction of messenger RNA into cells > 1 ⁇ 10 4 HeLa cells were seeded in each well of a 96-well transparent flat-bottomed white plastic plate and cultured in a CO 2 incubator at 37° C. for one day. After that, cells in each well were transfected with mRNA using 0.2 ⁇ l of Lipofectamine MessengerMAX (Thermo Fisher Scientific).
- ⁇ Luciferase assay> After culturing the cells in a CO 2 incubator at 37°C for 1-2 days after transfection, luciferase analysis of Luc2 and NanoLuc respectively was performed using the Nano-Glo Dual-Luciferase Reporter Assay System (Promega) and the GloMax Navigator Microplate Luminometer (Promega). Activity was measured. After correcting the luminescence of Luc2 with the luminescence of NanoLuc, which is a transfection control, it was expressed as a relative value with the value of the negative control group in each experiment set to 1.
- Example 1 eDHFR Sensing-Induced Translational Repression in Plasmid DNA Introduction
- translational control factors were split into RNA-binding proteins, each was fused with a caged intein and a target-binding molecule, a nanobody (antigen-binding domain of a single-chain antibody).
- Caliciviral VPg-based translational activator (CaVT, SEQ ID NO: 11), which can be used for both translational repression and translational activation by changing the sequence of the switch mRNA to be controlled, was selected as the translational control factor to be split.
- both cleaved CaVT fragments bind to the target protein via nanobodies.
- the caged intein acts to reconstitute full-length CaVT and bind to the switch mRNA (Figs. 1 and 2).
- Caged intein is based on DnaE intein derived from Nostoc punctiforme (Npu), and reconstruction with Npu DnaE intein requires that the N-terminal amino acid in the C-terminal fragment is cysteine. Since the CaVT RNA-binding protein contains two cysteines, residues 46 and 88, a plasmid that expresses a CaVT split at one of these positions fused with the Npu DnaE intein DNA was constructed (Fig. 4(A)).
- this plasmid DNA uses the original Npu DnaE intein instead of a caged intein, even if the target protein is not present, CaVT can be reactivated if both the N-terminal and C-terminal CaVT fragments are present. composition occurs.
- these plasmid DNAs were introduced into HeLa cells together with a Luc2-expressing plasmid DNA with a strong CaVT-binding motif added to the 5' untranslated region so that CaVT would repress translation, the split at residue 46 showed a Luc2 translational repression was observed when both CaVT fragment and C-terminal CaVT fragment were expressed. On the other hand, no clear inhibition of translation was observed in the one split at the 88th residue (Fig. 4(B)).
- Example 2 Translation repression and translation activation induced by detection of eDHFR in mRNA transfection Since translation repression by detection of eDHFR was confirmed in plasmid DNA, next, split CaVT and its translational control target were introduced by mRNA. We decided to investigate whether it is possible to detect eDHFR and induce translational repression. HeLa cells were transfected with mRNA expressing split CaVT, mRNA expressing eDHFR, and Luc2 mRNA with a strong CaVT-binding motif added to the 5' untranslated region to be subject to translational repression by CaVT. , Luc2 translational repression was induced in response to eDHFR only when both N-terminal and C-terminal fragments of split CaVT were introduced (Figs. 6A and 6B).
- Non-Patent Document 1 Luc2 mRNA with the structure required for translational activation by CaVT was prepared and introduced into HeLa cells together with split CaVT mRNA and eDHFR mRNA. However, translational activation in response to eDHFR was observed only (Figs. 6A and 6C).
- Example 3 EGFP detection-induced translational repression and translational activation in mRNA transfection Any protein can be detected and translational repression or translational activation can be induced by altering the site of the nanobody that binds to the target protein.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
[1] 以下の(a)、(b)及び(c):
(a)標的分子の第1部位を特異的に認識する第1の標的結合分子と、ケージドインテインのN末端ドメインと、翻訳制御因子のN末端ドメインとを含む第1の融合タンパク質を発現するmRNA、
(b)標的分子の第2部位を特異的に認識する第2の標的結合分子と、ケージドインテインのC末端ドメインと、前記翻訳制御因子のC末端ドメインとを含む第2の融合タンパク質を発現するmRNA、
(c)前記翻訳制御因子を特異的に認識する1以上の結合モチーフと、目的タンパク質をコードする核酸配列とを含むスイッチmRNA、
またはこれらをコードするDNAを含み、
前記翻訳制御因子が、RNA結合タンパク質を含む、タンパク質の翻訳制御システム。
[2] 前記(a)のmRNAが、前記第1の融合タンパク質をコードする核酸配列を含む第1のmRNAであり、前記(b)のmRNAが、前記第2の融合タンパク質をコードする核酸配列を含む第2のmRNAである、[1]に記載のシステム。
[3] 前記(a)のmRNAと、前記(b)のmRNAが、5'から3'の向きに、前記第2の融合タンパク質をコードする核酸配列と、自己切断ペプチドをコードする自己切断配列と、前記第1の融合タンパク質をコードする核酸配列とを含む単一のmRNAである、[1]に記載のシステム。
[4] 前記翻訳制御因子が、RNA結合タンパク質と、翻訳活性化因子とを含む、[1]~[3]のいずれか1項に記載のシステム。
[5] 前記翻訳制御因子のN末端ドメインが、前記RNA結合タンパク質の第1の部分を含み、前記翻訳制御因子のC末端ドメインが、前記RNA結合タンパク質の第2の部分と、前記翻訳活性化因子とを含む[1]~[4]のいずれか1項に記載のシステム。
[6] 前記ケージドインテインのN末端ドメインが、ケージドeNpu N-インテインもしくはその変異体であり、前記ケージドインテインのC末端ドメインが、ケージドNpu C-インテインもしくはその変異体である、[1]~[5]のいずれか1項に記載のシステム。
[7] 前記スイッチmRNAが、
(A)前記翻訳制御因子により翻訳抑制されるオフスイッチmRNA、および/または
(B)前記翻訳制御因子により翻訳活性化されるオンスイッチmRNA
であり、
前記オフスイッチmRNAが、5’末端にCap構造もしくはCapアナログを備え、前記RNA結合タンパク質を特異的に認識する1以上の結合モチーフと、第1の目的タンパク質をコードする核酸配列とを含み、
前記オンスイッチmRNAが、7-メチルグアノシン5'-リン酸構造を有さず、前記RNA結合タンパク質を特異的に認識する1以上の結合モチーフと、第2の目的タンパク質をコードする核酸配列とを含む、
[1]~[6]のいずれか1項に記載のシステム。
[8] 前記RNA結合タンパク質がMS2CPである、[1]~[7]のいずれか1項に記載のシステム。
[9] 前記MS2CPに対する結合モチーフが、下記の式(I):
N1~N15は、それぞれ独立して、A、C、G又はUを表し;
RはG又はAを表し;
YはU又はCを表し;
N1とN15とは、N2とN14とは、N3とN13とは、N4とN12とは、N5とN11とは、N6とN10とは、及びN7とN9とは、それぞれ塩基対又はゆらぎ塩基対を形成する。)
で表される潜在的二次構造を有する、[8]に記載のシステム。
[10] 前記オフスイッチmRNAが、前記MS2CPを特異的に認識する2以上の結合モチーフを含み、当該2以上の結合モチーフの少なくとも2つが、RNAの足場構造を介して連結されている、[8]または[9]に記載のシステム。
[11] [1]~[10]のいずれか1項に記載のシステムを、細胞に導入する工程を含む、タンパク質の翻訳制御方法。
以下の(a)、(b)及び(c):
(a)標的分子の第1部位を特異的に認識する第1の標的結合分子と、ケージドインテインのN末端ドメインと、翻訳制御因子のN末端ドメインとを含む第1の融合タンパク質を発現するmRNA、
(b)標的分子の第2部位を特異的に認識する第2の標的結合分子と、ケージドインテインのC末端ドメインと、前記翻訳制御因子のC末端ドメインとを含む第2の融合タンパク質を発現するmRNA、
(c)前記翻訳制御因子を特異的に認識する1以上の結合モチーフと、目的タンパク質をコードする核酸配列とを含むスイッチmRNA、
またはこれらをコードするDNAを含み、
前記翻訳制御因子が、RNA結合タンパク質を含む。
)、配列番号3で示されるアミノ酸配列において1若しくは数個(例えば、2個、3個、4個、5個)のアミノ酸が欠失、置換、挿入及び/若しくは付加されたアミノ酸配列、又は配列番号3で示されるアミノ酸配列と85%以上(例:90%、95%、96%、97%、98%、99%又はそれ以上)の同一性を有するアミノ酸配列を含むタンパク質を用いることができる。本明細書において、「VPgタンパク質」には、VPgタンパク質、VPgタンパク質改変体やそれらの断片も包含されるものとする。
スイッチmRNAは、翻訳制御因子により翻訳制御されるmRNAである。スイッチmRNAには、翻訳制御因子により翻訳活性化されるオンスイッチmRNAと、翻訳抑制されるオフスイッチmRNAとがある。オンスイッチmRNAと、オフスイッチmRNAは、いずれも、翻訳制御因子を構成するRNA結合タンパク質を特異的に認識する1以上の結合モチーフと、目的タンパク質をコードする核酸配列とを含む。結合モチーフとは、特定のRNA結合タンパク質を特異的に認識し、RNA-タンパク質複合体形成する核酸配列をいう。以下に、オンスイッチmRNAと、オフスイッチmRNAの設計と構造について説明する。
オフスイッチmRNAは、5’末端にCap構造もしくはCapアナログを備え、翻訳制御因子を構成するRNA結合タンパク質を特異的に認識する1以上の結合モチーフと、第1の目的タンパク質をコードする核酸配列とを含む。
N1~N15は、それぞれ独立して、A、C、G又はUを表し;
RはG又はAを表し;
YはU又はCを表し;
N1とN15とは、N2とN14とは、N3とN13とは、N4とN12とは、N5とN11とは、N6とN10とは、及びN7とN9とは、それぞれ塩基対又はゆらぎ塩基対を形成する。)
で表される潜在的二次構造を有するRNAが挙げられる。一態様において、N1がA、N2がG又はC(好ましくはG)、N3がG、N4がU、N5がG、N6がG、N7がG、N8がU、N9がC、N10がC、N11がC、N12がA、N13がU、N14がC又はG(好ましくはC)、N15がU、RがA、YがCである構造が挙げられる。
(式中、
N1~N15、R及びYの定義は上記に記載の通りであり;;
Xa及びXbは、それぞれ独立して、A、G、C又はUであり;
n及びmは、それぞれ独立して、0以上の整数を表し;
Xaは、Xbと共に、バルジループを有していてもよいステム構造を構成する。)
で表される潜在的二次構造を有するRNAが挙げられる。式(II)におけるn及びmは、それぞれ独立して、典型的には、1000以下、好ましくは、100以下(例:50、20、10等)の整数である。
オンスイッチmRNAは、5'末端に7-メチルグアノシン5'-リン酸構造を有さず、翻訳制御因子を構成するRNA結合タンパク質を特異的に認識する結合モチーフと、第2の目的タンパク質をコードする核酸配列とを含む。
〈pDNAの構築〉
PCRによるインサートの作製はPrimeSTAR Max DNA Polymerase(タカラバイオ)を用いて行い、Monarch PCR & DNA Cleanup Kit(New England Biolabs)にて精製した。また、クローニングはIn-Fusion HD Cloning Kit(タカラバイオ)を用いて行った。pDNAは大腸菌DH5α株またはHST08株にて増幅し、Monarch plasmid miniprep kit (New England Biolabs)を用いて精製した。DNAの濃度測定にはNanodrop ONE(Thermo Fisher Scientific)を用いた。構築したプラスミドの配列はサンガーDNAシーケンシングサービス(Genewiz)にて確認した。プラスミドの名称と配列番号を以下の表2に示す。
テンプレートDNAはPrimeSTAR Max DNA Polymeraseを用いたPCRにて作製し、Monarch PCR & DNA Cleanup Kit(New England Biolabs)にて精製した。このテンプレートDNAを鋳型として、MEGAscript T7 Transcription Kit(Thermo Fisher Scientific)を用いて37℃の転写反応を約6時間行った。またこの際、6 mMのATP、CTP、GTP、N1-メチルシュードUTPならびに4.8 mMのCleanCap Reagnt AG (3’OMe)(TriLink)をNTPならびにCapアナログとして用いた。反応終了後、RNACleanXP(日本ジェネティクス)にて精製し、Quick CIP(New England Biolabs)にて37℃脱リン酸化反応を30分間行ってから、RNeasy Mini Kit(Qiagen)にて精製した。RNA濃度はNanodrop ONEにて測定した。また、精製後のmRNAのサイズはBioanalyzerとRNA 6000ナノキット(アジレント・テクノロジー株式会社)を用いて確認した。テンプレートDNAの名称と配列番号を以下の表3に示す。
96ウェル透明平底白色プラスチックプレートの各ウェルに1×104個のHeLa細胞を撒き、37℃のCO2インキュベーターにて一日間培養した。その後、TransIT-X2(タカラバイオ)0.3 μlにて各ウェルの細胞にpDNAをトランスフェクションした。
96ウェル透明平底白色プラスチックプレートの各ウェルに1×104個のHeLa細胞を撒き、37℃のCO2インキュベーターにて一日間培養した。その後、Lipofectamine MessengerMAX(Thermo Fisher Scientific)0.2 μlにて各ウェルの細胞にmRNAをトランスフェクションした。
トランスフェクションから1~2日間37℃のCO2インキュベーターにて細胞を培養した後、Nano-Glo Dual-Luciferase Reporter Assay System(Promega)とGloMax Navigator Microplate Luminometer(Promega)を用いてLuc2とNanoLucそれぞれのルシフェラーゼ活性を測定した。Luc2の発光はトランスフェクションコントロールであるNanoLucの発光で補正した後、各実験におけるネガティブコントロール群の値を1とする相対値で表した。
標的タンパク質の存在下でのみスイッチmRNAの翻訳を抑制または活性化するため、翻訳制御因子をRNA結合タンパク質内で分割し、それぞれにケージドインテインと、標的結合分子であるナノボディ(一本鎖抗体の抗原結合ドメイン)を融合させた。分割する翻訳制御因子としては、制御対象のスイッチmRNAの配列を変えることで翻訳抑制にも翻訳活性化にも用いることが可能なCaliciviral VPg-based Translational activator(CaVT、配列番号11)を選択した。標的タンパク質が存在すると、分割されたCaVTの両断片がナノボディを介して標的タンパク質に結合する。これによりケージドインテインの働きで完全長のCaVTが再構成されてスイッチmRNAに結合するという仕組みである(図1、2)。
プラスミドDNAではeDHFR検知による翻訳抑制が確認できたため、次に、分割CaVTやその翻訳制御対象をmRNAで導入した場合もeDHFRを検知して翻訳抑制を引き起こせるかを検討することにした。図3と同じ構成の分割CaVTを発現するmRNA、eDHFRを発現するmRNA、ならびにCaVTにより翻訳抑制を受けるよう5’非翻訳領域に強いCaVT結合モチーフを付加したLuc2 mRNAをともにHeLa細胞に導入したところ、分割CaVTのN末端側とC末端側両断片を導入した場合にのみ、eDHFRに応答してLuc2の翻訳抑制が誘導された(図6A、6B)。
標的タンパク質に結合するナノボディの部位を変更すればどのようなタンパク質でも検知して翻訳抑制または翻訳活性化を誘導できるという本システムの汎用性を示すため、分割CaVTのナノボディ部分をeDHFRに結合するNb113とCA1698からEGFPに結合するLag16とGFP enhancer Nbに変更したものを構築した。このEGFP検知用に設計した分割CaVTのmRNAを、EGFP mRNAならびに強いCaVT結合モチーフを持つLuc2 mRNAとともにHeLa細胞に導入したところ、実施例2の場合と同様に、標的タンパク質によりLuc2の翻訳抑制が誘導された(図7A、7B)。また、Luc2 mRNAとして弱いCaVT結合モチーフとA-Capを持つものを用いた場合も、実施例2と同様に標的タンパク質依存的に翻訳活性化が引き起こされた(図7A、7C)。以上の結果より、本システムの汎用性が示されたといえる。
Claims (11)
- 以下の(a)、(b)及び(c):
(a)標的分子の第1部位を特異的に認識する第1の標的結合分子と、ケージドインテインのN末端ドメインと、翻訳制御因子のN末端ドメインとを含む第1の融合タンパク質を発現するmRNA、
(b)標的分子の第2部位を特異的に認識する第2の標的結合分子と、ケージドインテインのC末端ドメインと、前記翻訳制御因子のC末端ドメインとを含む第2の融合タンパク質を発現するmRNA、
(c)前記翻訳制御因子を特異的に認識する1以上の結合モチーフと、目的タンパク質をコードする核酸配列とを含むスイッチmRNA、
またはこれらをコードするDNAを含み、
前記翻訳制御因子が、RNA結合タンパク質を含む、タンパク質の翻訳制御システム。 - 前記(a)のmRNAが、前記第1の融合タンパク質をコードする核酸配列を含む第1のmRNAであり、前記(b)のmRNAが、前記第2の融合タンパク質をコードする核酸配列を含む第2のmRNAである、請求項1に記載のシステム。
- 前記(a)のmRNAと、前記(b)のmRNAが、5'から3'の向きに、前記第2の融合タンパク質をコードする核酸配列と、自己切断ペプチドをコードする自己切断配列と、前記第1の融合タンパク質をコードする核酸配列とを含む単一のmRNAである、請求項1に記載のタンパク質の翻訳制御システム。
- 前記翻訳制御因子が、RNA結合タンパク質と、翻訳活性化因子とを含む、請求項1~3のいずれか1項に記載のシステム。
- 前記翻訳制御因子のN末端ドメインが、前記RNA結合タンパク質の第1の部分を含み、前記翻訳制御因子のC末端ドメインが、前記RNA結合タンパク質の第2の部分と、前記翻訳活性化因子とを含む請求項1~4のいずれか1項に記載のシステム。
- 前記ケージドインテインのN末端ドメインが、ケージドeNpu N-インテインもしくはその変異体であり、前記ケージドインテインのC末端ドメインが、ケージドNpu C-インテインもしくはその変異体である、請求項1~5のいずれか1項に記載のシステム。
- 前記スイッチmRNAが、
(A)前記翻訳制御因子により翻訳抑制されるオフスイッチmRNA、および/または
(B)前記翻訳制御因子により翻訳活性化されるオンスイッチmRNA
であり、
前記オフスイッチmRNAが、5’末端にCap構造もしくはCapアナログを備え、前記RNA結合タンパク質を特異的に認識する1以上の結合モチーフと、第1の目的タンパク質をコードする核酸配列とを含み、
前記オンスイッチmRNAが、7-メチルグアノシン5'-リン酸構造を有さず、前記RNA結合タンパク質を特異的に認識する1以上の結合モチーフと、第2の目的タンパク質をコードする核酸配列とを含む、
請求項1~6のいずれか1項に記載のシステム。 - 前記RNA結合タンパク質がMS2CPである、請求項1~7のいずれか1項に記載のシステム。
- 前記オフスイッチmRNAが、前記MS2CPを特異的に認識する2以上の結合モチーフを含み、当該2以上の結合モチーフの少なくとも2つが、RNAの足場構造を介して連結されている、請求項8または9に記載のシステム。
- 請求項1~10のいずれか1項に記載のシステムを、細胞に導入する工程を含む、タンパク質の翻訳制御方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021-139141 | 2021-08-27 | ||
JP2021139141 | 2021-08-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023027170A1 true WO2023027170A1 (ja) | 2023-03-02 |
Family
ID=85322942
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/032192 WO2023027170A1 (ja) | 2021-08-27 | 2022-08-26 | タンパク質の翻訳制御システム |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023027170A1 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020537646A (ja) * | 2017-10-12 | 2020-12-24 | ザ ジャクソン ラボラトリーThe Jackson Laboratory | トランスジェニック選択方法および組成物 |
-
2022
- 2022-08-26 WO PCT/JP2022/032192 patent/WO2023027170A1/ja active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020537646A (ja) * | 2017-10-12 | 2020-12-24 | ザ ジャクソン ラボラトリーThe Jackson Laboratory | トランスジェニック選択方法および組成物 |
Non-Patent Citations (13)
Title |
---|
COTTON ET AL., NUCL. ACID. RES., vol. 19, 1991, pages 2629 - 2635 |
GRAHN E ET AL., RNA, vol. 7, no. 11, 2001, pages 1616 - 1627 |
GRAMESPACHER J. A. ET AL., J. AM. CHEM. SOC., vol. 141, no. 35, 2019, pages 13708 - 13712 |
GRAMESPACHER JOSEF A., BURTON ANTONY J., GUERRA LUIS F., MUIR TOM W.: "Proximity Induced Splicing Utilizing Caged Split Inteins", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, vol. 141, no. 35, 4 September 2019 (2019-09-04), pages 13708 - 13712, XP093038942, ISSN: 0002-7863, DOI: 10.1021/jacs.9b05721 * |
H. NAKANISHIH. SAITO, NATURE COMMUNICATIONS, vol. 11, no. 1, 10 March 2020 (2020-03-10), pages 1297 |
HOBBS ET AL., BIOCHEMISTRY, vol. 12, 1973, pages 5138 - 5145 |
KAWASAKI S. ET AL., NUCLEIC ACIDS RES., vol. 45, no. 12, 2017, pages e117 |
NAKANISHI HIDEYUKI, SAITO HIROHIDE: "Caliciviral protein-based artificial translational activator for mammalian gene circuits with RNA-only delivery", NATURE COMMUNICATIONS, vol. 11, no. 1, XP093038940, DOI: 10.1038/s41467-020-15061-x * |
RAHMAN S.M.A.SEKI S.OBIKA S.YOSHIKAWA H.MIYASHITA K.IMANISHI T., J. AM. CHEM. SOC., vol. 130, 2008, pages 4886 - 4896 |
SHI X ET AL., NAT CHEM BIOL., vol. 12, no. 3, 2016, pages 146 - 152 |
SPROAT ET AL., NUCLE. ACID. RES., vol. 19, 1991, pages 733 - 738 |
TETRAHEDRON LETT., vol. 38, 1997, pages 8735 - 8738 |
TETRAHEDRON, vol. 59, 2003, pages 5123 - 5128 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lee et al. | The structure of human SFPQ reveals a coiled-coil mediated polymer essential for functional aggregation in gene regulation | |
Lemm et al. | Ongoing U snRNP biogenesis is required for the integrity of Cajal bodies | |
Robbins et al. | Stable expression of shRNAs in human CD34+ progenitor cells can avoid induction of interferon responses to siRNAs in vitro | |
Vogel et al. | A small, portable RNA device for the control of exon skipping in mammalian cells | |
Feng et al. | A multifunctional lentiviral-based gene knockdown with concurrent rescue that controls for off-target effects of RNAi | |
Rivas-Aravena et al. | The Elav-like protein HuR exerts translational control of viral internal ribosome entry sites | |
KR102536221B1 (ko) | 단백질 생산을 위한 지질 대사의 조정 | |
US20100226901A1 (en) | Genetic control of mammalian cells with synthetic rna regulatory systems | |
ES2970541T3 (es) | Plataforma de cribado CRISPR/CAS para identificar modificadores genéticos de la siembra o agregación de tau | |
Roithová et al. | The Sm-core mediates the retention of partially-assembled spliceosomal snRNPs in Cajal bodies until their full maturation | |
JP2010523130A (ja) | Rna干渉タグ | |
Tucker et al. | Selection and characterization of a DNA aptamer specifically targeting human HECT ubiquitin ligase WWP1 | |
CN111088323A (zh) | 筛选跨膜靶蛋白适配体的细胞selex方法及跨膜靶蛋白适配体及其应用 | |
WO2023027170A1 (ja) | タンパク質の翻訳制御システム | |
CN115698301A (zh) | 活性dna转座子系统及其使用方法 | |
Long et al. | RNAe in a transgenic growth hormone mouse model shows potential for use in gene therapy | |
Leontovyc et al. | Synthetic mRNA is a more reliable tool for the delivery of DNA-targeting proteins into the cell nucleus than fusion with a protein transduction domain | |
WO2017209122A1 (ja) | 標的mRNAからのタンパク質発現量を向上させるための融合タンパク質 | |
WO2023027169A1 (ja) | 生細胞の選別システム | |
TWI515203B (zh) | 衍生自雞貧血病毒(cav)vp2蛋白質的細胞核定位信號胜肽以及它們的應用 | |
US20220098682A1 (en) | Enhanced cell based screening platform for anti-hbv therapeutics | |
US20240011004A1 (en) | Compositions comprising a variant crispr nuclease polypeptide and uses thereof | |
WO2023100955A1 (ja) | Rna分子 | |
WO2024010028A1 (ja) | 環状rna分子及びこれを用いた翻訳制御方法、翻訳活性化システム、並びに医薬組成物 | |
WO2013151058A1 (ja) | miR-140の発現を制御するDNA及び該DNAを利用した薬剤のスクリーニング方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22861458 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2023544000 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022861458 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022861458 Country of ref document: EP Effective date: 20240327 |